Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$24.89 -0.4%	$21.05	$15.47 ▼ $36.37	$851.56M	1.26	205,657 shs	221,896 shs
HCM HUTCHMED	$15.43 -1.8%	$14.62	$11.51 ▼ $21.50	$2.69B	0.52	99,966 shs	39,187 shs
IMVT Immunovant	$15.86 +3.6%	$15.04	$12.72 ▼ $34.47	$2.71B	0.61	1.22 million shs	1.23 million shs
PTGX Protagonist Therapeutics	$53.92 -2.3%	$47.72	$30.67 ▼ $60.60	$3.34B	2.25	898,596 shs	918,437 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+5.33%	+19.32%	+27.51%	+42.15%
HCM HUTCHMED	0.00%	-12.92%	+16.28%	+2.94%	-13.36%
IMVT Immunovant	0.00%	-0.50%	+5.73%	-19.25%	-39.44%
PTGX Protagonist Therapeutics	0.00%	-4.26%	+15.68%	+2.41%	+65.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.4385 of 5 stars	3.6	0.0	2.6	0.8	0.0
HCM HUTCHMED	1.3464 of 5 stars	2.0	2.0	2.0	0.0	1.9
IMVT Immunovant	1.2782 of 5 stars	3.5	0.0	1.4	1.7	0.0
PTGX Protagonist Therapeutics	1.5547 of 5 stars	2.5	2.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	57.84% Upside
HCM HUTCHMED	2.00	Hold	$19.00	23.14% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	141.70% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	22.59% Upside

Current Analyst Ratings Breakdown

Latest AVBP, PTGX, HCM, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00
4/10/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00 ➝ $70.00
3/20/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
3/20/2025	IMVT Immunovant	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
HCM HUTCHMED	$630.20M	4.27	$0.29 per share	53.72	$4.43 per share	3.48
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	7.69	$4.52 per share	11.94	$11.33 per share	4.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.57	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	71.89	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)

Latest AVBP, PTGX, HCM, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
HCM HUTCHMED	0.08	2.83	2.70
IMVT Immunovant	N/A	11.16	11.16
PTGX Protagonist Therapeutics	N/A	17.25	17.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
HCM HUTCHMED	3.60%
IMVT Immunovant	5.90%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable
IMVT Immunovant	120	170.92 million	160.84 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable

AVBP, PTGX, HCM, and IMVT Headlines

Recent News About These Companies

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLC

June 19 at 3:53 AM | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Citigroup

June 19 at 1:27 AM | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Citigroup

June 17 at 8:34 AM | marketbeat.com

Assenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 17 at 3:34 AM | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $65.44 Average Target Price from Analysts

June 17 at 2:09 AM | americanbankingnews.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 13, 2025 | marketbeat.com

Arturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

June 12, 2025 | insidertrades.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 Shares

June 11, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street Zen

June 8, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 7, 2025 | marketbeat.com

Short Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%

June 5, 2025 | marketbeat.com

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

June 4, 2025 | benzinga.com

Protagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC Wainwright

June 3, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial Corp

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Wellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 80,877 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen

June 1, 2025 | marketbeat.com

340,974 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Toronto Dominion Bank

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, PTGX, HCM, and IMVT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$24.89 -0.09 (-0.36%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$24.91 +0.02 (+0.08%)

As of 06/18/2025 04:04 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

HUTCHMED NASDAQ:HCM

$15.43 -0.28 (-1.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.55 +0.12 (+0.77%)

As of 06/18/2025 04:42 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$15.86 +0.55 (+3.59%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.86 0.00 (-0.03%)

As of 06/18/2025 05:41 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Protagonist Therapeutics NASDAQ:PTGX

$53.92 -1.29 (-2.34%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$53.92 +0.00 (+0.01%)

As of 06/18/2025 04:39 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time